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Case Report
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aureus (MRSA) Purulent Pericarditis in the Setting of
Endocarditis
Samiullah Arshad, MD,a and Naoki Misumida, MD, FACC, FSCAIb
a
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ABSTRACT



RESUM
E

Methicillin-resistant Staphylococcus aureus (MRSA) purulent pericarditis is a rare but potentially fatal complication of MRSA bacteremia.
We describe a case of a 27-year-old patient with active intravenous
drug use, who presented with fever, chills, and dyspnea and was found
to have tricuspid valve endocarditis. Echocardiogram on admission
showed no pericardial effusion. The patient became hypotensive, with
worsening dyspnea, in the following 3 days. A computed tomography
scan of the chest was repeated and showed a large pericardial effusion. The patient underwent pericardiocentesis and pericardial drain
placement. Antibiotics were continued, with resolution of effusion.
Early pericardiocentesis of a large purulent pericardial effusion may
prevent catastrophic outcomes.
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Community-acquired methicillin-resistant Staphylococcus
aureus (MRSA) infection is increasingly seen in patients who
use intravenous drugs, who are 16 times more likely to
develop an invasive infection than nonedrug users.1 The
proportion of invasive MRSA infections has increased from
4.1% in 2011 to 9.2% in 2016, per the Centers for Disease
Control and Prevention.1 However, MRSA pericarditis is not
commonly encountered in the current antibiotic era. Here, we
report a case of purulent pericarditis that developed rapidly, in
3 days, despite the patient being on appropriate antibiotic
therapy.

Case
A 27-year-old woman with active intravenous drug use
disorder presented with fever, cough, and shortness of breath.
She reported the use of heroin 14 days prior to presentation.
At presentation, her blood pressure was 100/70 mm Hg, heart
rate 90 beats per minute, temperature 98.4 F, and oxygen
saturation 91% on room air. Physical exam revealed basilar
crackles on bilateral lung bases; cardiovascular exam was
limited due to body habitus, but no murmur was identiﬁed on
presentation.
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Initial investigations
The initial white blood cell count was 21,200 per mL, and
erythrocyte sedimentation rate was 95. Initial chest radiograph
showed scattered cavitary nodules (Supplemental Fig. S1A). A
computed tomography (CT) scan of the chest showed innumerable cavitary lung nodules scattered throughout the lungs
consistent with septic emboli. Echocardiogram showed a
mobile structure in the right atrium, consistent with vegetation on tricuspid leaﬂets with trace tricuspid regurgitation. No
pericardial effusion was seen on admission (Fig. 1). Blood
cultures were positive for MRSA.
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Novel Teaching Points
 MRSA purulent pericarditis may develop very rapidly in
patients with MRSA bacteremia. Our report highlights
the development of this complication in the span of 3
days.
 Our literature review suggests that the more common
cause of MRSA purulent pericarditis is hematogenous
seeding of the pericardium. However, patients should
be screened for periannular complications if hemodynamic deterioration occurs.
 Early pericardiocentesis in a patient with stable hemodynamics should be considered to drain a large purulent
pericardial effusion in the setting of MRSA endocarditis,
to prevent tamponade, which may evolve very rapidly.

Management
The patient was diagnosed with tricuspid valve infective
endocarditis due to MRSA, complicated by multiple septic
emboli. She was promptly started on intravenous vancomycin
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on presentation. Over the next 3 days, the patient continued
to have worsening dyspnea. On day 3, the patient became
hypotensive, with a blood pressure of 90/48 mm Hg, and
tachycardic, with a heart rate of 115 beats per minute and
new-oxygen requirement of 4 L supplemental oxygen via nasal
cannula to maintain saturation above 88%. A chest radiograph showed worsening bilateral pulmonary inﬁltrates and a
new right pleural effusion (Supplemental Fig. S1B). After
ﬂuid resuscitation, a repeat chest CT scan done for concern
for lung abscess and empyema incidentally showed a
moderate-to-large pericardial effusion (Supplemental
Fig. S1C) and a moderate-size pleural effusion concerning
for empyema. The patient did not have an obviously elevated
jugular venous pressure, but assessment was difﬁcult because
of obesity. Pulsus paradoxus was not checked. A repeat
echocardiogram showed moderate-size pericardial effusion
with signiﬁcant respiratory inﬂow variation across the
tricuspid valve, inferior vena cava dilation but without
chamber collapse, consistent with an early echocardiographic
sign of cardiac tamponade (Fig. 2). No periannular extension
of infection was seen on transthoracic echocardiogram. A
transesophageal echocardiogram was not done. Tranthoracic
echocardiogram and ﬂuroscopy-guided pericardiocentesis was

Figure 1. Echocardiogram upon admission. (A) Parasternal long-axis view revealed no pericardial effusion. (B) Right ventricular (RV) inﬂow view
revealed a vegetation (white arrow) attached to tricuspid leaﬂet. (C) Apical 4-chamber view. RA, right atrium.
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Figure 2. Echocardiogram on day 3. (A) Parasternal long-axis view revealed moderate-size circumferential pericardial effusion. (B) Apical 4-chamber
view revealed moderate-size circumferential pericardial effusion. (C) Pulse-wave Doppler across the tricuspid valve revealed signiﬁcant respiratory
inﬂow variation. Every third cardiac cycle is associated with absent tricuspid inﬂow, presumably during expiration, with the patient breathing at a rate
of 30/min, consistent with tamponade.

performed in the cardiac catheterization lab via a subxiphoid
approach. A needle was inserted into the pericardium, and
then a J-tipped wire was inserted into the pericardial space and
conﬁrmed by ﬂuoroscopy. A dilator was advanced, and the
wire was exchanged for a .035 J 260 cm Amplatz Super Stiff
guide. An 8.3 F pigtail pericardial drain was then inserted over
the wire and sutured into place. A total of 270 cc of bloody
ﬂuid was drained. Post-procedure blood pressure improved to
132/73 mm Hg. Pericardial ﬂuid analysis revealed 892,500
per mL red blood cells, 3275 per mL nucleated cell, and a
lactate dehydrogenase level of 1540 U/L. A pericardial ﬂuid
culture grew MRSA. Pericardial drain output stopped in 2
days, and the drain was removed 3 days after placement. A
repeat echocardiogram showed an absence of pericardial ﬂuid
re-accumulation (Supplemental Fig. S2). Blood cultures
became sterile within 5 days after presentation. Thoracentesis
followed by chest tube placement for right pleural collection
was completed 1 day after the pericardial drain placement, and
pleural ﬂuid analysis was consistent with empyema. Our plan
was to continue intravenous vancomycin for 6 weeks, but the
patient left the hospital against medical advice after having
received 2 weeks of intravenous antibiotics.
Discussion
Pericarditis is an inﬂammation of the pericardium, which
can be associated with accumulation of pericardial ﬂuid.
Pericarditis is broadly categorized into infectious and noninfectious etiologies. Infectious causes include those that are
viral, bacterial, fungal, and parasitic; noninfectious causes

include those that neoplastic, auto-immune, metabolic, and
drug-related.2
Bacterial pericarditis can be caused by hematogenous
spread of bacteria, penetrating injury to the thoracic cavity, or
direct spread from the surrounding structures, including the
lungs, esophagus, and diaphragm, including the myocardium.
Bacterial pericarditis is most commonly caused by Staphylococcus, Streptococcus, and tuberculous bacteria. Prior studies
have reported S. aureus as the cause of pericarditis in 22% to
31% of cases.3
MRSA purulent pericarditis leading to tamponade is a rare
but potentially fatal complication of MRSA bacteremia. A
search of the literature on PubMed and Google Scholar for
terms of MRSA pericarditis revealed 40 documented reports
of MRSA pericarditis in adults, as summarized in
Supplemental Table S1. Among these case reports, there were
47 patients, of which 5 patients (10%) used intravenous
drugs. Cardiac tamponade was diagnosed in 29 patients
(61%), and 31 patients (66%) underwent pericardiocentesis
with drainage. Surgical intervention was done in 22 patients
(47%), of whom 10 (21%) underwent pericardial window
drainage, 5 (11%) underwent pericardiectomy, and 7 (15%)
underwent concomitant mediastinal interventions for management of the infection.
Regueiro et al.4 reported that the prevalence of small-tomoderate pericardial effusions in the setting of infective
endocarditis between 1990 and 2007 was 23%, and the
prevalence of large pericardial effusions was 2%. Small-tomoderate pericardial effusions were more common in rightsided endocarditis in the setting of intravenous drug use.
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High circulating titers of immune complexes, a proinﬂammatory state, and immune response to infective endocarditis were proposed as causes of the effusion. Large
pericardial effusions usually arise from periannular abscess
with ﬁstula formation and myocardial destruction extending
to the pericardium. However, the study identiﬁed that large
pericardial effusions also can be caused by hematogenous
spread of S. aureus in the absence of periannular complications. A follow-up study by Regueiro et al.,5 using the Spanish
Collaboration on endocarditis from 2007 to 2013, noted that
7.8% was mild-to-moderate pericardial effusion, and 0.5%
was large pericardial effusion. Of 6 cases of large pericardial
effusion, 2 were caused by S. aureus. Youssef et al.,6 in their
study of 338 patients with endocarditis, highlighted that the
presence of pericardial effusion in native or prosthetic valve
endocarditis gave patients a worse prognosis, compared with
that for patients without pericardial effusion. Further studies
are needed to quantify the proportion of purulent vs serous
collections in moderate and large pericardial effusions in the
setting of endocarditis.
A review of the literature on cases of MRSA pericarditis
revealed that only 1 patient had endomyocardial extension of
the infection (Tani et al. in Supplemental Table S1) leading to
pericardial effusion, with the remaining cases with likely hematogenous seeding of the pericardium leading to pericarditis.
Hematogenous seeding was likely the mechanism of pericardial effusion in our patient. Another possible mechanism for
the development of pericarditis in our patient is the contiguous spread of infection from the lungs in the setting of septic
emboli and empyema.
Clinical features of purulent pericarditis, including classic
positional chest pain, pericardial friction rub, and electrical
alternans, may be absent in the initial few days. An echocardiogram is the most sensitive way to identify pericardial
effusion; signiﬁcant pericardial effusion can also be identiﬁed on a CT chest scan, as in our case. Typical echocardiographic signs of tamponade, including prominent right
atrial and right ventricular collapse in the setting of clinical
tamponade, may be absent in severe pulmonary hypertension and severe right ventricular hypertrophy.7 Respiratory
septal motion may be attenuated in the setting of a rigid
hypertrophied septum. Our patient had subtle echocardiographic signs of early tamponade, and lacked the right atrial/
right ventricular collapse, without any of the above conditions masking them. Tamponade is not an all-or-none
phenomenon; hence, both clinical and early echocardiographic ﬁndings should be taken into consideration for
decision-making about intervention. The rapid improvement in hemodynamics post-pericardiocentesis supports the
diagnosis of cardiac tamponade. More than half of patients
with MRSA pericarditis developed cardiac tamponade, and
about half of them required surgical drainage. Hence, for a
large pericardial effusion in the setting of endocarditis, we
recommend early intervention to prevent sudden hemodynamic compensation, as the purulent ﬂuid may rapidly
collect in the pericardial space.
Pericardial ﬂuid analysis usually reveals a low glucose level
and increased white and red blood cell counts, with an
elevated lactate dehydrogenase level indicative of exudative
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pericardial effusion. The rapid development and progression
of purulent effusion to cardiac tamponade is near fatal in 85%
of cases if left untreated.8
Management includes antibiotics and drainage. Drainage
usually includes pericardial drain placement with control of
bacteremia. Intrapericardial streptokinase may help dissolve
the septations and improve drainage. Surgical interventions
include pericardiotomy and pericardial window placement,
which may be needed for recurrent accumulations.
Conclusion
Our case and review of the literature highlight the fact that
patients with MRSA endocarditis can rapidly develop a large
purulent pericardial effusion, and early pericardiocentesis may
prevent a catastrophic outcome.
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